RT Journal Article
SR Electronic
T1 FRI0216 Detection of structural lesions on t1 weighted mri versus radiography of the si joints in early axial spondyloarthritis: 2-year data
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 648
OP 649
DO 10.1136/annrheumdis-2018-eular.2124
VO 77
IS Suppl 2
A1 Maksymowych, W.P.
A1 Claudepierre, P.
A1 de Hooge, M.
A1 Lambert, R.G.
A1 Landewé, R.
A1 Molto, A.
A1 van der Heijde, D.
A1 Bukowski, J.F.
A1 Jones, H.
A1 Logeart, I.
A1 Marshall, L.
A1 Pedersen, R.
A1 Szumski, A.
A1 Vlahos, B.
A1 Dougados, M.
YR 2018
UL http://ard.bmj.com/content/77/Suppl_2/648.3.abstract
AB Background Sacroiliac joint (SIJ) structural damage may be evaluated using MRI, CT scan or radiographs.Objectives A post-hoc analysis of SIJ images from EMBARK (NCT01258738) and DESIR (NCT01648907) evaluated:1 association between presence/absence of erosion on MRI and presence/absence of erosion or sacroiliitis on radiographs at BL and Wk 104;2 association between decrease/increase in erosion score on MRI and decrease/increase in erosion or sacroiliitis grade on radiographs, BL to Wk 104.Methods All patients had early axSpA. EMBARK: 12 wks double-blind placebo-control, then 92 wks open-label etanercept. DESIR: patients had no history of biologics and received no biologics for 104 wks. MRI images from both studies: combined, anonymized, and read per patient; radiographs combined, anonymized, read separately from MRI. Readers unaware of: image chronology, original cohort. Three experienced readers individually reviewed T1 weighted MRI using SpondyloArthritis Research Consortium of Canada SIJ Structural Score; 3 different readers assessed radiographic sacroiliitis using mNY grade; all were at level of each joint surface. Lesion presence/absence or decrease/increase recorded per patient if ≥2 of 3 readers agreed. Statistical analyses: κ coefficient of agreement, McNemar’s test for discordance asymmetry.Results 224 patients had MRI and radiographs. At BL, concordance for presence or absence of erosion in 162/224 (72.3%) (κ=0.42), table 1. Discordance: erosion more frequent on MRI (21.4%) than radiographs (6.3%; p<0.0001). Wk 104 data similar to BL. Decrease in erosion more frequent than increase only on MRI; significantly more frequent on MRI than radiographs. Decrease in erosion on MRI significantly more frequent than decrease in sacroiliitis grade.View this table:Abstract FRI0216 – Table 1 Concordance between MRI and Radiographs, BL and Wk 104; and Change BL to Wk 104Conclusions Findings of SIJ structural damage are observed differently on radiography and MRI in patients with early axSpA, and may appear to evolve differently.Disclosure of Interest W. Maksymowych Grant/research support from: AbbVie, Pfizer, Consultant for: Abbvie, Janssen, Lilly, Merck, Novartis, Pfizer, UCB, P. Claudepierre Consultant for: Abbvie, BMS, Celgene, Janssen, Novartis, Merck, Pfizer, Roche, UCB, Lilly, M. de Hooge Employee of: Selfemployed without other personnel (registered company under the Belgium law) MdH Research. Additional Affiliation: Ghent University, Ghent, Belgium, R. Lambert Consultant for: AbbVie, Bioclinica, Janssen, Parexel, UCB, R. Landewé Grant/research support from: Abbott, Amgen, Centocor, Novartis, Pfizer, Roche, Schering-Plough, UCB, Consultant for: AbbVie, Ablynx, Amgen, Astra-Zeneca, Bristol Myers Squibb, Celgene, Janssen, Galapagos, GlaxoSmithKline, Novartis, Novo-Nordisk, Merck, Pfizer, Roche, Schering-Plough, TiGenix, UCB, Employee of: Director of Rheumatology Consultancy BV, which is a registered company under Dutch law, Speakers bureau: Abbott/AbbVie, Amgen, Bristol Myers Squibb, Janssen, Merck, Pfizer, Roche, Schering-Plough, UCB, A. Molto Grant/research support from: Pfizer, Consultant for: Merck, UCB, D. van der Heijde Consultant for: AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB, Employee of: Director of Imaging Rheumatology bv, J. Bukowski Shareholder of: Pfizer, Employee of: Pfizer, H. Jones Shareholder of: Pfizer, Employee of: Pfizer, I. Logeart Shareholder of: Pfizer, Employee of: Pfizer, L. Marshall Shareholder of: Pfizer, Employee of: Pfizer, R. Pedersen Shareholder of: Pfizer, Employee of: Pfizer, A. Szumski Employee of: InVentiv Health, B. Vlahos Shareholder of: Pfizer, Employee of: Pfizer, M. Dougados Grant/research support from: Pfizer, AbbVie, UCB, Merck and Lilly, Consultant for: Pfizer, AbbVie, UCB, Merck and Lilly